Last reviewed · How we verify
PIB 0.2% ropivacaine
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local infiltration anesthesia, Regional anesthesia and nerve blocks, Perioperative pain management.
At a glance
| Generic name | PIB 0.2% ropivacaine |
|---|---|
| Also known as | ropivacaine 0.2% Programmed intermittent bolus |
| Sponsor | University Health Network, Toronto |
| Drug class | Local anesthetic (amide class) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly inhibits sodium influx into nerve fibers, which stabilizes the neuronal membrane and prevents depolarization. This action blocks conduction of sensory, motor, and autonomic nerve impulses in the area where it is administered. The 0.2% concentration represents a dilute formulation suitable for infiltration anesthesia and regional anesthetic techniques.
Approved indications
- Local infiltration anesthesia
- Regional anesthesia and nerve blocks
- Perioperative pain management
Common side effects
- Injection site reactions (pain, erythema)
- Transient paresthesia
- Systemic toxicity (CNS effects, cardiac arrhythmias) with overdose
- Allergic reactions
Key clinical trials
- Continuous Serratus Anterior Blockade for Sternotomy (NA)
- Local Anesthetic Automated Intermittent Administration vs. Continuous Infusion Via Femoral Nerve Block. (PHASE4)
- PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIB 0.2% ropivacaine CI brief — competitive landscape report
- PIB 0.2% ropivacaine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI